Logo image of THRX

THESEUS PHARMACEUTICALS INC (THRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:THRX - US88369M1018 - Common Stock

4.06 USD
0 (0%)
Last: 2/13/2024, 8:11:21 PM
4.08 USD
+0.02 (+0.49%)
After Hours: 2/13/2024, 8:11:21 PM
Fundamental Rating

3

THRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. THRX has a great financial health rating, but its profitability evaluates not so good. THRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year THRX has reported negative net income.
THRX had a negative operating cash flow in the past year.
THRX Yearly Net Income VS EBIT VS OCF VS FCFTHRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

With a decent Return On Assets value of -24.13%, THRX is doing good in the industry, outperforming 60.70% of the companies in the same industry.
Looking at the Return On Equity, with a value of -25.22%, THRX is in the better half of the industry, outperforming 70.65% of the companies in the same industry.
Industry RankSector Rank
ROA -24.13%
ROE -25.22%
ROIC N/A
ROA(3y)-57.73%
ROA(5y)N/A
ROE(3y)-68.96%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THRX Yearly ROA, ROE, ROICTHRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 200 -200 -400

1.3 Margins

THRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
THRX Yearly Profit, Operating, Gross MarginsTHRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022

More info and screens

9

2. Health

2.1 Basic Checks

The number of shares outstanding for THRX remains at a similar level compared to 1 year ago.
There is no outstanding debt for THRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
THRX Yearly Shares OutstandingTHRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M
THRX Yearly Total Debt VS Total AssetsTHRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 9.94 indicates that THRX is not in any danger for bankruptcy at the moment.
THRX has a Altman-Z score of 9.94. This is amongst the best in the industry. THRX outperforms 85.57% of its industry peers.
There is no outstanding debt for THRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.94
ROIC/WACCN/A
WACCN/A
THRX Yearly LT Debt VS Equity VS FCFTHRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 29.94 indicates that THRX has no problem at all paying its short term obligations.
The Current ratio of THRX (29.94) is better than 97.51% of its industry peers.
A Quick Ratio of 29.94 indicates that THRX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 29.94, THRX belongs to the best of the industry, outperforming 98.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 29.94
Quick Ratio 29.94
THRX Yearly Current Assets VS Current LiabilitesTHRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for THRX have decreased strongly by -12.61% in the last year.
EPS 1Y (TTM)-12.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.83% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-0.43%
EPS Next 2Y12.36%
EPS Next 3Y13%
EPS Next 5Y16.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
THRX Yearly Revenue VS EstimatesTHRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 100M 200M 300M 400M
THRX Yearly EPS VS EstimatesTHRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

THRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year THRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
THRX Price Earnings VS Forward Price EarningsTHRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
THRX Per share dataTHRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

THRX's earnings are expected to grow with 13.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.36%
EPS Next 3Y13%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for THRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THESEUS PHARMACEUTICALS INC

NASDAQ:THRX (2/13/2024, 8:11:21 PM)

After market: 4.08 +0.02 (+0.49%)

4.06

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-17 2023-11-17/amc
Earnings (Next)03-07 2024-03-07/amc
Inst Owners0.03%
Inst Owner Change0%
Ins Owners13.19%
Ins Owner Change0%
Market Cap181.28M
Revenue(TTM)N/A
Net Income(TTM)-56.62M
Analysts77.78
Price Target5.36 (32.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.53%
Min EPS beat(2)7.48%
Max EPS beat(2)15.58%
EPS beat(4)4
Avg EPS beat(4)16.53%
Min EPS beat(4)7.48%
Max EPS beat(4)22.6%
EPS beat(8)6
Avg EPS beat(8)6.59%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.44%
EPS NY rev (1m)0%
EPS NY rev (3m)10.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 0.81
EV/EBITDA N/A
EPS(TTM)-1.34
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0
BVpS5.03
TBVpS5.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.13%
ROE -25.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.73%
ROA(5y)N/A
ROE(3y)-68.96%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 29.94
Quick Ratio 29.94
Altman-Z 9.94
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
EPS Next Y-0.43%
EPS Next 2Y12.36%
EPS Next 3Y13%
EPS Next 5Y16.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.03%
OCF growth 3YN/A
OCF growth 5YN/A

THESEUS PHARMACEUTICALS INC / THRX FAQ

What is the ChartMill fundamental rating of THESEUS PHARMACEUTICALS INC (THRX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to THRX.


Can you provide the valuation status for THESEUS PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to THESEUS PHARMACEUTICALS INC (THRX). This can be considered as Overvalued.


How profitable is THESEUS PHARMACEUTICALS INC (THRX) stock?

THESEUS PHARMACEUTICALS INC (THRX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for THESEUS PHARMACEUTICALS INC?

The Earnings per Share (EPS) of THESEUS PHARMACEUTICALS INC (THRX) is expected to decline by -0.43% in the next year.